Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Hospices Civils de Lyon
Modality
protein_peptide
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
56High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06158334CT.gov Study of Surgical Practices in Patients With Haemophilia A or B Treated With an Extended Half-life Recombinant Factor VIII-Fc or IX-Fc (ELOCTA®, ALPROLIX®) | — | Unknown | — | — | — |
NCT03901755CT.gov An International Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B | — | Completed | — | — | — |
NCT03655340CT.gov A Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B in France | — | Completed | — | — | — |
NCT03248141CT.gov Understanding Hemophilia A and B Drug Dosage Administration Patterns | — | Terminated | — | — | — |
NCT03055611CT.gov A Study to Evaluate the Real-world Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or B | — | Completed | — | — | — |
NCT03075670CT.gov A Trial Comparing Nonacog Beta Pegol (N9-GP) and ALPROLIX® in Patients With Haemophilia B | — | Completed | — | — | — |
NCT02392156CT.gov Fc factOrs and Real-World hemophiliA Patient-ReporteD Outcomes | — | Terminated | — | — | — |
NCT02234310CT.gov Study to Determine the Safety and Efficacy of rFIXFc in Previously Untreated Males With Severe Hemophilia B | — | Completed | — | — | — |
NCT01440946CT.gov Study of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in Previously Treated Pediatric Participants With Hemophilia B | — | Completed | — | — | — |
NCT00716716CT.gov Phase I/IIa Study of FIXFc in Hemophilia B Patients | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hemophilia B
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Eftrenonacog Alfa (this asset) | Hospices Civils de Lyon | P3 | BB · 64 |
| Eptacog Alfa (Activated) | AryoGen Pharmed Co. | P4 | A |
| Factor Ix | CSL Behring | P4 | A |
| Nonacog Alfa | Pfizer | P4 | A |
| Nonacog Beta Pegol | Novo Nordisk A/S | P3 | A |
| Coagulation Factor Viia | American Thrombosis and Hemostasis Network | P4 | BBB |
| Albutrepenonacog Alfa | CSL Behring | P3 | BBB |
| Fitusiran | Genzyme, a Sanofi Company | P3 | BBB |
| Bax 326 | Baxalta now part of Shire | P3 | BB |
+40 more in the Hemophilia B cohort
Other indications for Eftrenonacog Alfa
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Severe Hemophilia B | — | P3 | BB · 66 |
| Inherited Blood Coagulation Disorder | — | P1 | CC · 47 |
| Hemophilia A | — | Unk | D · 30 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Eftrenonacog Alfa in Hemophilia B. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/eftrenonacog-alfa-hemophilia-b
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →